Teva $1 Billion Market Depends on New Test of Laquinimod

Teva Pharmaceutical Industries Ltd. is recruiting about 1,800 patients for a new trial of its multiple sclerosis pill in a bid to improve how the disease is treated and secure a successor to its best-selling medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.